Outlook Sees Finish Line For Ophthalmic Bevacizumab

The US FDA Issued CRL Last Year Over CMC Issues And Lack Of Evidence

 
• By Urtė Fultinavičiūtė
  
Man walking a tightrope between two buildings
Outlook’s product would be the first approved ophthalmic formulation of bevacizumab • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products